Calamos Advisors LLC Purchases New Shares in KORU Medical Systems, Inc. (NASDAQ:KRMD)

Calamos Advisors LLC purchased a new position in shares of KORU Medical Systems, Inc. (NASDAQ:KRMD - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 64,989 shares of the company's stock, valued at approximately $250,000. Calamos Advisors LLC owned approximately 0.14% of KORU Medical Systems as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in shares of KORU Medical Systems in the third quarter worth about $34,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of KORU Medical Systems by 77.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 61,412 shares of the company's stock valued at $168,000 after purchasing an additional 26,860 shares in the last quarter. Empire Financial Management Company LLC acquired a new stake in shares of KORU Medical Systems during the third quarter worth approximately $259,000. Finally, Geode Capital Management LLC increased its stake in shares of KORU Medical Systems by 6.5% in the third quarter. Geode Capital Management LLC now owns 462,128 shares of the company's stock worth $1,262,000 after buying an additional 28,323 shares during the last quarter. Hedge funds and other institutional investors own 58.60% of the company's stock.

Analyst Ratings Changes

KRMD has been the topic of a number of research analyst reports. Craig Hallum increased their price objective on shares of KORU Medical Systems from $5.00 to $6.00 and gave the company a "buy" rating in a research note on Friday, January 17th. Canaccord Genuity Group increased their price target on shares of KORU Medical Systems from $3.00 to $4.00 and gave the stock a "buy" rating in a research report on Thursday, November 14th. Piper Sandler boosted their price objective on KORU Medical Systems from $3.00 to $3.50 and gave the company an "overweight" rating in a report on Thursday, November 14th. Finally, Lake Street Capital increased their target price on KORU Medical Systems from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Tuesday, January 14th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $4.50.

KORU Medical Systems Stock Performance

Shares of NASDAQ KRMD traded down $0.23 during midday trading on Friday, hitting $4.62. The company's stock had a trading volume of 236,592 shares, compared to its average volume of 259,462. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.37 and a current ratio of 2.99. KORU Medical Systems, Inc. has a 1-year low of $2.01 and a 1-year high of $5.05. The firm's fifty day moving average price is $4.08 and its 200-day moving average price is $3.16. The firm has a market cap of $211.78 million, a P/E ratio of -18.48 and a beta of 0.45.

KORU Medical Systems Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.